RESUMEN
Middle East respiratory syndrome (MERS) remains a serious international public health threat. With the goal of accelerating the development of countermeasures against MERS coronavirus (MERS-CoV), funding agencies, nongovernmental organizations, and researchers across the world assembled in Riyadh, Saudi Arabia, on November 14-15, 2015, to discuss vaccine development challenges. The meeting was spearheaded by the Saudi Ministry of Health and co-organized by the International Vaccine Institute, South Korea. Accelerating the development of a preventive vaccine requires a better understanding of MERS epidemiology, transmission, and pathogenesis in humans and animals. A combination of rodent and nonhuman primate models should be considered in evaluating and developing preventive and therapeutic vaccine candidates. Dromedary camels should be considered for the development of veterinary vaccines. Several vaccine technology platforms targeting the MERS-CoV spike protein were discussed. Mechanisms to maximize investment, provide robust data, and affect public health are urgently needed.
Asunto(s)
Infecciones por Coronavirus/veterinaria , Coronavirus del Síndrome Respiratorio de Oriente Medio/inmunología , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales , Investigación Biomédica , Camelus , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/virología , Humanos , Cooperación Internacional , Coronavirus del Síndrome Respiratorio de Oriente Medio/metabolismo , Arabia Saudita , Glicoproteína de la Espiga del Coronavirus/inmunología , Glicoproteína de la Espiga del Coronavirus/metabolismoRESUMEN
The WHO Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on strategic priorities, activities and technical issues related to global efforts to develop vaccines against malaria. MALVAC convened a series of meetings to obtain expert, impartial consensus views on the priorities and best practice for vaccine-related research and development strategies. The technical areas covered during these consultations included: guidance on clinical trial design for candidate sporozoite and asexual blood stage vaccines; measures of efficacy of malaria vaccines in Phase IIb and Phase III trials; standardization of immunoassays; the challenges of developing assays and designing trials for interventions against malaria transmission; modelling impact of anti-malarial interventions; whole organism malaria vaccines, and Plasmodium vivax vaccine-related research and evaluation. These informed discussions and opinions are summarized here to provide guidance on harmonization of strategies to help ensure high standards of practice and comparability between centres and the outcome of vaccine trials.
Asunto(s)
Descubrimiento de Drogas/tendencias , Vacunas contra la Malaria/inmunología , Vacunas contra la Malaria/aislamiento & purificación , Malaria Vivax/prevención & control , Humanos , Organización Mundial de la SaludAsunto(s)
Acceso a la Información , Recolección de Datos/métodos , Planificación en Desastres/métodos , Urgencias Médicas , Difusión de la Información/métodos , Salud Pública/métodos , Brasil , Recolección de Datos/normas , Salud Global , Humanos , Salud Pública/normas , Organización Mundial de la Salud , Virus Zika , Infección por el Virus ZikaRESUMEN
Development and Phase 3 testing of the most advanced malaria vaccine, RTS,S/AS01, indicates that malaria vaccine R&D is moving into a new phase. Field trials of several research malaria vaccines have also confirmed that it is possible to impact the host-parasite relationship through vaccine-induced immune responses to multiple antigenic targets using different platforms. Other approaches have been appropriately tested but turned out to be disappointing after clinical evaluation. As the malaria community considers the potential role of a first-generation malaria vaccine in malaria control efforts, it is an apposite time to carefully document terminated and ongoing malaria vaccine research projects so that lessons learned can be applied to increase the chances of success for second-generation malaria vaccines over the next 10 years. The most comprehensive resource of malaria vaccine projects is a spreadsheet compiled by WHO thanks to the input from funding agencies, sponsors and investigators worldwide. This spreadsheet, available from WHO's website, is known as "the rainbow table". By summarizing the published and some unpublished information available for each project on the rainbow table, the most comprehensive review of malaria vaccine projects to be published in the last several years is provided below.
Asunto(s)
Investigación Biomédica/tendencias , Ensayos Clínicos como Asunto , Descubrimiento de Drogas/tendencias , Vacunas contra la Malaria/inmunología , Malaria/epidemiología , Malaria/prevención & control , Bases de Datos Factuales , Humanos , Internet , Vacunas contra la Malaria/administración & dosificación , Organización Mundial de la SaludRESUMEN
The World Health Organization (WHO) convened a malaria vaccines committee (MALVAC) scientific forum from 20 to 21 February 2012 in Geneva, Switzerland, to review the global malaria vaccine portfolio, to gain consensus on approaches to accelerate second-generation malaria vaccine development, and to discuss the need to update the vision and strategic goal of the Malaria Vaccine Technology Roadmap. This article summarizes the forum, which included reviews of leading Plasmodium falciparum vaccine candidates for pre-erythrocytic vaccines, blood-stage vaccines, and transmission-blocking vaccines. Other major topics included vaccine candidates against Plasmodium vivax, clinical trial site capacity development in Africa, trial design considerations for a second-generation malaria vaccine, adjuvant selection, and regulatory oversight functions including vaccine licensure.
Asunto(s)
Descubrimiento de Drogas/tendencias , Vacunas contra la Malaria/inmunología , Plasmodium falciparum/inmunología , Plasmodium vivax/inmunología , Humanos , Malaria Falciparum/prevención & control , Malaria Vivax/prevención & controlAsunto(s)
Vacunas contra la Malaria , Malaria Falciparum/prevención & control , Femenino , Humanos , MasculinoAsunto(s)
Urgencias Médicas , Difusión de la Información/métodos , Salud Pública/métodos , Recolección de Datos/ética , Recolección de Datos/legislación & jurisprudencia , Recolección de Datos/métodos , Salud Global , Humanos , Difusión de la Información/ética , Difusión de la Información/legislación & jurisprudencia , Salud Pública/ética , Salud Pública/legislación & jurisprudenciaRESUMEN
In animals, effective immune responses against malignancies and against several infectious pathogens, including malaria, are mediated by T cells. Here we show that a heterologous prime-boost vaccination regime of DNA either intramuscularly or epidermally, followed by intradermal recombinant modified vaccinia virus Ankara (MVA), induces high frequencies of interferon (IFN)-gamma-secreting, antigen-specific T-cell responses in humans to a pre-erythrocytic malaria antigen, thrombospondin-related adhesion protein (TRAP). These responses are five- to tenfold higher than the T-cell responses induced by the DNA vaccine or recombinant MVA vaccine alone, and produce partial protection manifest as delayed parasitemia after sporozoite challenge with a different strain of Plasmodium falciparum. Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans.
Asunto(s)
Inmunización Secundaria , Vacunas contra la Malaria/inmunología , Linfocitos T/inmunología , Vacunas de ADN/inmunología , Vacunas Sintéticas/inmunología , Virus Vaccinia/inmunología , Animales , Antígenos de Protozoos/inmunología , Humanos , Esquemas de Inmunización , Interferón gamma/inmunología , Interferón gamma/metabolismo , Activación de Linfocitos , Malaria Falciparum/prevención & control , Malaria Falciparum/terapia , Péptidos/inmunología , Péptidos/metabolismo , Plásmidos , Plasmodium falciparum/genética , Plasmodium falciparum/inmunología , Proteínas Protozoarias/inmunología , Linfocitos T/metabolismo , Virus Vaccinia/genéticaRESUMEN
The RTS,S/AS candidate malaria vaccine has demonstrated efficacy against a variety of endpoints in Phase IIa and Phase IIb trials over more than a decade. A multi-country phase III trial of RTS,S/AS01 is now underway with submission as early as 2012, if vaccine safety and efficacy are confirmed. The immunologic basis for how the vaccine protects against both infection and disease remains uncertain. It is, therefore, timely to review the information currently available about the vaccine with regard to how it impacts the human-Plasmodium falciparum host-pathogen relationship. In this article, what is known about mechanisms involved in partial protection against malaria induced by RTS,S is reviewed.
Asunto(s)
Benzamidas/farmacología , Vacunas contra la Malaria/inmunología , Malaria Falciparum/inmunología , Malaria Falciparum/prevención & control , Plasmodium falciparum/inmunología , Piridinas/farmacología , Animales , Ensayos Clínicos como Asunto , HumanosRESUMEN
BACKGROUND: Recent years have seen publication of a considerable number of clinical trials of preventive interventions against clinical malaria in children. There has been variability in the specification of end-points, case definitions, analysis methods and reporting and the relative lack of standardization complicates the ability to make comparative evaluations between trials. METHODS: To prepare for a WHO consultation on design issues in malaria vaccine trials, controlled trials of preventive interventions against malaria in children in endemic countries were identified in which clinical malaria, or death, had been one of the main end-points. Trials were included that evaluated the impact of vaccines, insecticide-treated bed nets (ITN), intermittent presumptive or preventive therapy in infants (IPTi) or, in one instance, vitamin A supplementation. Methods that had been used in these trials were summarized and compared in order to identify issues that were directly relevant to the design of malaria vaccine trials. RESULTS: 29 controlled trials of preventive malaria interventions were identified, of which eight were vaccine trials. Vaccine trials that were designed to detect an effect on clinical malaria all reported the incidence rate of first episodes of clinical malaria as their primary endpoint. Only one trial of a preventive intervention (of ITN) was identified that was designed to detect an effect on severe malaria. A group of larger trials were designed to detect an effect of impregnated bed nets or curtains on all-cause mortality as the primary end-point. Key methodological and reporting differences between trials are noted in the text. Two issues have been identified that are of some concern. Firstly, the choice of primary endpoint is not stated in the reports of a number of the trials and, secondly, the relationship between pre-specified analysis plans and trial reports is rarely made clear. CONCLUSION: This article reports an investigation into the ways in which trial design and reporting could be improved and standardized to enable comparative evaluation of the relative merits of malaria control measures, and specifically with respect to the design of malaria vaccine trials. The need for standardization of clinical trial design, conduct, analysis and reporting has been also affirmed as a priority area by the Malaria Vaccine Technology Roadmap.
Asunto(s)
Vacunas contra la Malaria/administración & dosificación , Malaria/prevención & control , Control de Mosquitos/métodos , Parasitemia/prevención & control , Animales , Niño , Ensayos Clínicos como Asunto , Determinación de Punto Final , Humanos , Lactante , Malaria/parasitología , Pediatría , Ensayos Clínicos Controlados Aleatorios como Asunto , Proyectos de Investigación , Resultado del TratamientoRESUMEN
Respiratory syncytial virus (RSV) is a leading viral cause of respiratory morbidity and mortality in infants and young children worldwide. Low and middle income countries (LMICs) account for approximately 99% of the global mortality estimates in this population, with up to 200,000 RSV deaths per year. The vaccine product development pipeline is diverse with the most advanced clinical candidate currently in phase III efficacy testing in pregnant women. In addition, a long-acting RSV-neutralizing monoclonal antibody (mAb) to be administered at birth to prevent serious RSV-related respiratory disease is in late stage clinical development, as are additional conventional mAb for use in high-risk infants. Thus, there is a realistic possibility that an effective new intervention to prevent RSV disease will be available in the next 5-10year horizon. In anticipation of this outcome, the Strategic Advisory Group of Experts for Immunization (SAGE), WHO's vaccine policy recommendation body, reviewed the status of RSV vaccine and monoclonal antibody development in April 2016. Although substantial progress towards licensure has broadened the research agenda to consider intervention impact and cost effectiveness, significant gaps remain in the data that will be needed to inform and support a policy recommendation for implementation. These aspects were the focus of WHO's second consultation on RSV vaccines and single dosage extended half-life mAb for prophylaxis.
Asunto(s)
Infecciones por Virus Sincitial Respiratorio/inmunología , Vacunas contra Virus Sincitial Respiratorio/inmunología , Virus Sincitial Respiratorio Humano/inmunología , Infecciones del Sistema Respiratorio/inmunología , Humanos , Inmunización/métodos , Derivación y Consulta , Vacunación/métodos , Organización Mundial de la SaludRESUMEN
Globally, group B Streptococcus (GBS) remains a leading cause of sepsis and meningitis in infants in the first 90days of life. Intrapartum antibiotic prophylaxis (IAP) for women at increased risk of transmitting GBS to their newborns has been effective in reducing part, but not all, of the GBS disease burden in many high income countries (HICs). In low- and middle-income countries (LMICs), IAP use is low. Immunization of pregnant women with a GBS vaccine represents an alternative strategy to protecting newborns and young infants, through transplacental antibody transfer and potentially by reducing new vaginal colonization. This vaccination strategy was first suggested in the 1970s and several potential GBS vaccines have completed phase I/II clinical trials. During the 2015 WHO Product Development for Vaccines Advisory Committee meeting, GBS was identified as a high priority for the development of a vaccine for maternal immunization because of the major public health burden posed by GBS in LMICs, and the high technical feasibility for successful development. Following this meeting, the first WHO technical consultation on GBS vaccines was held on the 27th and 28th of April 2016, to consider development pathways for such vaccines, focused on their potential role in reducing newborn and young infant deaths and possibly stillbirths in LMICs. Discussion topics included: (1) pathophysiology of disease; (2) current gaps in the knowledge of global disease burden and serotype distribution; (3) vaccine candidates under development; (4) design considerations for phase III trials; and (5) pathways to licensure, policy recommendations and use. Efforts to address gaps identified in each of these areas are needed to establish the public health need for, the development and deployment of, efficacious GBS vaccines. In particular, more work is required to understand the global disease burden of GBS-associated stillbirths, and to develop quality-assured standardized antibody assays to identify correlates of protection.
Asunto(s)
Infecciones Estreptocócicas/inmunología , Vacunas Estreptocócicas/inmunología , Streptococcus agalactiae/crecimiento & desarrollo , Animales , Ensayos Clínicos como Asunto , Femenino , Humanos , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Embarazo , Complicaciones Infecciosas del Embarazo/inmunología , Complicaciones Infecciosas del Embarazo/microbiología , Mortinato , Infecciones Estreptocócicas/microbiología , Vacunación/métodos , Organización Mundial de la SaludAsunto(s)
Práctica Clínica Basada en la Evidencia , Política de Salud , Vacunas contra la Malaria/economía , Malaria/prevención & control , Vacunas Sintéticas/economía , Ensayos Clínicos Fase IV como Asunto , Análisis Costo-Beneficio , Toma de Decisiones , Enfermedades Endémicas/economía , Enfermedades Endémicas/prevención & control , Humanos , Inmunidad Innata , Lactante , Malaria/economía , Malaria/inmunología , Vacunas contra la Malaria/inmunología , Vacunas Sintéticas/inmunologíaRESUMEN
There are more vaccines in development, against a greater number of pathogens, than ever before. A challenge with this exceptional level of activity and investment is how to select and resource the most promising approaches to have the most significant impact on public health. The WHO Product Development for Vaccines Advisory Committee (PDVAC) was established in 2014 to provide strategic advice and recommendations to WHO for vaccines in clinical development that could have a significant impact on public health in low and middle income countries. On 7-9th September 2015, PDVAC was convened for the second time, when the committee reviewed vaccine developments in 24 disease areas. This report summarises the key recommendations from that consultation.
Asunto(s)
Comités Consultivos , Vacunación/tendencias , Vacunas/uso terapéutico , Organización Mundial de la Salud , Investigación Biomédica , Control de Enfermedades Transmisibles , Salud Global , Humanos , SuizaRESUMEN
Respiratory syncytial virus (RSV) is a globally prevalent cause of lower respiratory infection in neonates and infants. Despite its disease burden, a safe and effective RSV vaccine has remained elusive. In recent years, improved understanding of RSV biology and innovations in immunogen design has resulted in the advancement of multiple vaccine candidates into the clinical development pipeline. Given the growing number of vaccines in clinical trials, the rapid pace at which they are being tested, and the likelihood that an RSV vaccine will reach the commercial market in the next 5-10 years, consensus and guidance on clinical development pathways and licensure routes are needed now, before large-scale efficacy trials commence. In pursuit of this aim, the World Health Organization convened the first RSV vaccine consultation in 15 years on the 23rd and 24th of March, 2015 in Geneva, Switzerland. The meeting's primary objective was to provide guidance on clinical endpoints and development pathways for vaccine trials with a focus on considerations of low- and middle-income countries. Meeting participants reached consensus on candidate case definitions for RSV disease, considerations for clinical efficacy endpoints, and the clinical development pathway for active and passive immunization trials in maternal and pediatric populations. The strategic focus of this meeting was on the development of high quality, safe and efficacious RSV preventive interventions for global use and included: (1) maternal/passive immunization to prevent RSV disease in infants less than 6 months; (2) pediatric immunization to prevent RSV disease in infants and young children once protection afforded by maternal immunization wanes.
Asunto(s)
Ensayos Clínicos como Asunto , Descubrimiento de Drogas , Guías como Asunto , Inmunización/métodos , Infecciones por Virus Sincitial Respiratorio/prevención & control , Vacunas contra Virus Sincitial Respiratorio/inmunología , Vacunas contra Virus Sincitial Respiratorio/aislamiento & purificación , Humanos , Organización Mundial de la SaludRESUMEN
In 2014, the World Health Organization, the US National Institutes of Health, and global technical partners published a comprehensive roadmap for development of new vaccines against sexually transmitted infections (STIs). Since its publication, progress has been made in several roadmap activities: obtaining better epidemiologic data to establish the public health rationale for STI vaccines, modeling the theoretical impact of future vaccines, advancing basic science research, defining preferred product characteristics for first-generation vaccines, and encouraging investment in STI vaccine development. This article reviews these overarching roadmap activities, provides updates on research and development of individual vaccines against herpes simplex virus, Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum, and discusses important next steps to advance the global roadmap for STI vaccine development.